分子式C22H23N5O2 |
InChIKeyMPYACSQFXVMWNO-UHFFFAOYSA-N |
CAS号1206163-45-2 |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
斑块状银屑病 | 临床2期 | 德国 | 2013-03-01 | |
斑块状银屑病 | 临床2期 | 英国 | 2013-03-01 | |
系统性红斑狼疮 | 临床2期 | 阿根廷 | 2013-03-01 | |
系统性红斑狼疮 | 临床2期 | 智利 | 2013-03-01 | |
系统性红斑狼疮 | 临床2期 | 捷克 | 2013-03-01 | |
系统性红斑狼疮 | 临床2期 | 爱沙尼亚 | 2013-03-01 | |
系统性红斑狼疮 | 临床2期 | 法国 | 2013-03-01 | |
系统性红斑狼疮 | 临床2期 | 德国 | 2013-03-01 | |
系统性红斑狼疮 | 临床2期 | 希腊 | 2013-03-01 | |
系统性红斑狼疮 | 临床2期 | 中国香港 | 2013-03-01 |
临床2期 | 68 | Placebo | 餘蓋製廠築鬱觸壓衊艱(淵齋衊網廠遞範觸願築) = 齋醖衊範淵餘壓鏇遞遞 簾願廠夢簾遞範選網廠 (選蓋網鏇觸廠簾憲窪蓋, 範衊廠衊齋積衊鏇憲蓋 ~ 獵鬱淵艱獵範醖顧願網) 更多 | - | 2017-08-03 | ||
临床2期 | 50 | 蓋鬱廠壓蓋壓廠獵膚繭(鹽膚構構觸衊夢獵糧築) = Shortly thereafter, significant safety data were identified, including elevated liver enzymes in six patients (one confirmed and one suspected case of Drug Reaction with Eosinophilia and Systemic Symptoms), leading to immediate dosing cessation. 獵淵鏇選築構構選糧顧 (鏇壓製襯製餘顧鹽膚積 ) | 不佳 | 2016-11-01 | |||
Placebo | |||||||
N/A | 2 | GSK2586184 400 mg b.i.d. | 製窪膚鑰壓繭窪鹽壓築(艱鬱醖鹽積襯鬱鹽鬱獵) = GSK2586184 was well tolerated and no serious adverse events or drug related adverse events were reported 鏇鏇醖糧艱鹽鏇鹽築夢 (願願淵願製網夢製構夢 ) | 积极 | 2016-02-12 | ||
Placebo |